GleamWall
中文EN

COCP Cocrystal Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1412486 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY18.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-219.1%
ROA-131.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets60.5%
Debt / equity0.00x
Current ratio1.72x
Interest coverage122.45x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-28.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$105,000$105,000$225,000—————
R&D expense$1.98M$2.14M$1.37M$1.62M$954,000$1.12M$1.36M$2.04M
SG&A expense$1.62M$1.15M$1.21M$862,000$1.14M$986,000$981,000$1.19M
Operating income-$3.49M-$3.18M-$2.36M-$2.48M-$2.09M-$2.11M-$2.34M-$3.23M
Interest expense-$15,000-$10,000-$22,000-$47,000-$22,000-$28,000-$37,000-$55,000
Income tax$0$0$0—————
Net income-$3.44M-$3.16M-$2.30M-$2.43M-$2.05M-$2.06M-$2.30M-$3.27M
EBITDA-$3.48M-$3.17M-$2.34M-$2.47M-$2.08M-$2.09M-$2.32M-$3.20M
EPS (basic)-0.20-0.23-0.17—-0.19-0.20-0.23—
EPS (diluted)-0.20-0.23-0.17—-0.19-0.20-0.23—
Weighted avg. shares (diluted)17.42M13.79M13.79M—10.99M10.17M10.17M—
Balance sheet
Cash & equivalents$4.87M$2.17M$4.68M$7.03M$7.73M$4.77M$6.92M$9.86M
Current assets$5.51M$3.24M$5.94M$8.13M$8.78M$6.76M$8.83M$11.58M
PP&E, net$59,000$69,000$81,000$93,000$106,000$107,000$127,000$153,000
Total assets$6.77M$4.65M$7.43M$9.71M$10.45M$8.51M$10.66M$13.46M
Current liabilities$3.20M$2.62M$2.23M$2.21M$1.52M$1.83M$1.93M$2.43M
Total liabilities$4.10M$3.60M$3.31M$3.38M$2.78M$3.17M$3.35M$3.93M
Shareholders' equity$2.67M$1.04M$4.12M$6.33M$7.67M$5.33M$7.30M$9.52M
Shares outstanding19.26M13.79M13.79M13.78M13.04M10.17M10.17M10.17M
Cash flow statement
Operating cash flow-$2.30M-$2.52M-$2.34M-$1.74M-$1.36M-$2.15M-$2.94M-$3.16M
Capital expenditure———$0———$0
Free cash flow———-$1.74M———-$3.16M
Investing cash flow———$0———$0
Financing cash flow———$1.03M————
Depreciation & amortization$10,000$12,000$12,000$13,000$13,000$21,000$25,000$28,000
Stock-based compensation$74,000$92,000$84,000$56,000$48,000$84,000$82,000$85,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.